Journal of Medicinal Chemistry (7) Salvadori, S.; Fiorini, S.; Trapella, C.; Porreca, F.; Davis, P.; Sasaki, Y.; Ambo, A.; Marczak, E. D.; Lazarus, L. H.; Balboni, G. Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H- Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg. Med. Chem. 2008, 16 (6), 3032−3038. (8) (a) Fidock, D. A.; Rosenthal, P. J.; Croft, S. L.; Brun, R.; Nwaka, S. Antimalarial drug discovery: eﬃcacy models for compound screening. Nature Rev. Drug Discovery 2004, 3 (6), 509−520. (b) Vennerstrom, J. L.; Arbe-Barnes, S.; Brun, R.; Charman, S. A.; Chiu, F. C.; Chollet, J.; Dong, Y.; Dorn, A.; Hunziker, D.; Matile, H.; McIntosh, K.; Padmanilayam, M.; Santo Tomas, J.; Scheurer, C.; Scorneaux, B.; Tang, Y.; Urwyler, H.; Wittlin, S.; Charman, W. N. Identiﬁcation of an antimalarial synthetic trioxolane drug development candidate. Nature 2004, 430 (7002), 900−904. (9) Liu, B.; Chang, J.; Gordon, W. P.; Isbell, J.; Zhou, Y.; Tuntland, T. Snapshot PK: a rapid rodent in vivo preclinical screening approach. Drug Discovery Today 2008, 13 (7−8), 360−367. (10) Trager, W.; Jensen, J. B. Human malaria parasites in continuous culture. Science 1976, 193 (4254), 673−675. (11) (a) Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspeciﬁc binding to microsomes. Drug Metab. Dispos. 1999, 27 (11), 1350−1359. (b) Kalvass, J. C.; Tess, D. A.; Giragossian, C.; Linhares, M. C.; Maurer, T. S. Inﬂuence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data. Drug Metab. Dispos. 2001, 29 (10), 1332−1336. (c) Chauret, N.; Gauthier, A.; Nicoll-Griﬃth, D. A. Eﬀect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab. Dispos. 1998, 26 (1), 1−4. (d) Yan, Z.; Caldwell, G. W. Metabolic assessment in liver microsomes by co- activating cytochrome P450s and UDP-glycosyltransferases. Eur. J. Drug Metab. Pharmacokinet. 2003, 28 (3), 223−232. (12) (a) Avdeef, A.; Bendels, S.; Di, L.; Faller, B.; Kansy, M.; Sugano, K.; Yamauchi, Y. PAMPAcritical factors for better predictions of absorption. J. Pharm. Sci. 2007, 96 (11), 2893−2909. (b) Avdeef, A. The rise of PAMPA. Expert Opin. Drug Metab. Toxicol. 2005, 1 (2), 325−342. (13) Balimane, P. V.; Chong, S. Cell culture-based models for intestinal permeability: a critique. Drug Discovery Today 2005, 10 (5), 335−343. (14) (a) Dubin, A. E.; Nasser, N.; Rohrbacher, J.; Hermans, A. N.; Marrannes, R.; Grantham, C.; Van Rossem, K.; Cik, M.; Chaplan, S. R.; Gallacher, D.; Xu, J.; Guia, A.; Byrne, N. G.; Mathes, C. Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp. J. Biomol. Screening 2005, 10 (2), 168−181. (b) Mathes, C. QPatch: the past, present and future of automated patch clamp. Expert Opin Ther. Targets 2006, 10 (2), 319−327. (c) Zheng, W.; Spencer, R. H.; Kiss, L. High throughput assay technologies for ion channel drug discovery. Assay Drug Dev. Technol. 2004, 2 (5), 543− 552. (15) Franke-Fayard, B.; Trueman, H.; Ramesar, J.; Mendoza, J.; van der Keur, M.; van der Linden, R.; Sinden, R. E.; Waters, A. P.; Janse, C. J. A Plasmodium berghei reference line that constitutively expresses GFP at a high level throughout the complete life cycle. Mol. Biochem. Parasitol. 2004, 137 (1), 23−33. Article 4273 dx.doi.org/10.1021/jm300041e | J. Med. Chem. 2012, 55, 4244−4273